ProfessorMarkThursz

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Hepatology. Head of Department

Contact

+44 (0)20 3312 1903m.thursz

Assistant

Ms Dawn Campbell +44 (0)20 3312 6454

Location

Norfolk PlaceSt Mary's Campus

Summary

Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.

Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.

Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.

Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.

Publications

Journals

Lemoine M, 2023, Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study, The Lancet Global Health, Vol:11, ISSN:2214-109X, Pages:E1383-E1392

Vaikunthanathan T, Landmann E, Correa DM, et al.Vaikunthanathan T, Landmann E, Correa DM, Romano M, Trevelin SC, Peng Q, Crespo E, Corrado M, Lozano J-J, Pearce EL, Perpinan E, Zoccarato A, Siew L, Edwards-Hicks J, Khan R, Luu N-T, Thursz MR, Newsome PN, Martinez-Llordella M, Shah N, Lechler RI, Shah AM, Sanchez-Fueyo A, Lombardi G, Safinia N close, 2023, Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease., Ebiomedicine, Vol:95

Arab JP, Addolorato G, Mathurin P, et al.Arab JP, Addolorato G, Mathurin P, Thursz MR close, 2023, Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder., Clin Gastroenterol Hepatol, Vol:21, Pages:2124-2134

Thursz M, Sadiq F, Tree JA, et al.Thursz M, Sadiq F, Tree JA, Karayiannis P, Beasley DWC, Dejnirattisai W, Mongkolsapaya J, Screaton G, Wand M, Elmore MJ, Carroll MW, Matthews I, Thomas H close, 2023, Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2., J Gen Virol, Vol:104

Shimakawa Y, Ndow G, Kaneko A, et al.Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y, PROLIFICA/HBCRAG-RDT STUDY GROUP close, 2023, Rapid Point-of-Care Test for Hepatitis B Core-Related Antigen to Diagnose High Viral Load in Resource-Limited Settings., Clin Gastroenterol Hepatol, Vol:21, Pages:1943-1946.e2

More Publications